Salubris Pharmaceuticals' key drugs gain national medical insurance coverage

Shenzhen Salubris Pharmaceuticals has announced the inclusion of several key drugs in the National Medical Insurance Catalog for 2025. Xinchao Tuo (sacubitril valsartan calcium tablets) and Fuli An (alisartan indapamide sustained-release tablets) are newly added to Category B, while Ennaluo (ennadustat tablets) successfully renewed its inclusion. Additionally, Xilixin (alisartan ester tablets) has been reclassified under routine medical insurance management. The company anticipates these changes will take effect from January 1, 2026, to December 31, 2027.

In a related development, Salubris Pharmaceuticals received approval to initiate clinical trials for SAL0140 tablets, an innovative small molecule drug, targeting primary aldosteronism. This aldosterone synthase inhibitor aims to address unmet needs in conditions such as uncontrolled hypertension, primary aldosteronism, and chronic kidney disease.

These advancements underscore Salubris Pharmaceuticals' commitment to expanding its portfolio of innovative products, particularly in the cardiovascular and renal disease sectors. The inclusion of these drugs in the medical insurance catalog and the progress of new clinical trials are expected to enhance drug accessibility and address diverse patient needs, strengthening the company's position in chronic disease management.